<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41553169</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0946-1965</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2026</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of clinical pharmacology and therapeutics</Title><ISOAbbreviation>Int J Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetics and safety of a telmisartan/amlodipine/rosuvastatin fixed-dose combination tablet compared to co-administration of telmisartan/amlodipine and rosuvastatin in healthy Korean male volunteers.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.5414/CP204892</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study was conducted to compare the single-dose pharmacokinetic and safety profiles of JLP-1401 (fixed-dose combination (FDC) of telmisartan/amlodipine/rosuvastatin) to those of each constituent co-administered in healthy Korean male volunteers.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A total of 40 healthy Korean subjects participated in an open-label, randomized, single-dose, 4-period crossover study. During each treatment period, the subjects received the test drug (FDC tablet of telmisartan/amlodipine/rosuvastatin 80&#xa0;mg/10&#xa0;mg/20 mg) or reference drug (co-administration of telmisartan/amlodipine FDC tablet and rosuvastatin tablet). Plasma samples were collected pre dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72&#xa0;hours post dose to evaluate pharmacokinetic profiles. Safety was assessed by the evaluation of adverse events (AEs), laboratory assessments, 12-lead electrocardiograms, physical examinations, and vital sign measurements.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The geometric least-square mean ratios and their 90% confidence intervals of AUC<sub>last</sub> and C<sub>max</sub> were 1.01 (0.94&#xa0;-&#xa0;1.07) and 0.83 (0.72&#xa0;-&#xa0;0.95) for telmisartan, 1.01 (0.99&#xa0;-&#xa0;1.04) and 1.03 (1.01&#xa0;-&#xa0;1.06) for amlodipine, and 1.03 (0.98&#xa0;-&#xa0;1.08) and 0.94 (0.85&#xa0;-&#xa0;1.04) for rosuvastatin, respectively. All AEs were of mild or moderate intensity, and there were no significant differences in the incidence of AEs between the treatments.</AbstractText><AbstractText Label="DISCUSSION AND CONCLUSION" NlmCategory="CONCLUSIONS">The pharmacokinetic profiles of the test and reference drugs were within the bioequivalent criteria, and both drugs were safe and well tolerated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Seol Ju</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jeong-Soo</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Kwak</LastName><ForeName>Yong-Geun</ForeName><Initials>YG</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min-Gul</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Int J Clin Pharmacol Ther</MedlineTA><NlmUniqueID>9423309</NlmUniqueID><ISSNLinking>0946-1965</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41553169</ArticleId><ArticleId IdType="doi">10.5414/CP204892</ArticleId><ArticleId IdType="pii">192657</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41549823</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2160-7648</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical pharmacology in drug development</Title><ISOAbbreviation>Clin Pharmacol Drug Dev</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetic Interaction Among Amlodipine, Losartan, and Chlorthalidone after a Single Oral Administration in Healthy Male Subjects.</ArticleTitle><Pagination><StartPage>e70024</StartPage><MedlinePgn>e70024</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpdd.70024</ELocationID><Abstract><AbstractText>Antihypertensive drugs are more potent when administered in combinations of two or three different classes of drugs. The objective of this study was to evaluate the pharmacokinetic interaction among amlodipine, losartan, and chlorthalidone. A randomized, open-label, four-sequence, four-period, four-treatment, single-dose study was conducted in healthy Korean male subjects, with oral administrations of two tablets of amlodipine 5 mg, one tablet of losartan 100 mg, one tablet of chlorthalidone 25 mg, or co-administration of all three investigational products. Plasma drug concentrations were measured by liquid chromatography/tandem mass spectrometry. Twenty-six subjects completed the study. The geometric mean ratios and 90% confidence intervals of C<sub>max</sub> and AUC<sub>last,</sub> respectively, were 1.0928 (1.0412-1.1469) and 1.0360 (0.9958-1.0778) for amlodipine; 1.1016 (0.9136-1.3284) and 1.1606 (1.0885-1.2375) for losartan; 1.0720 (1.0119-1.1356) and 1.0902 (1.0350-1.1148) for EXP3174 (active metabolite of losartan); and 0.9462 (0.8626-1.0379) and 1.0266 (0.9752-1.0807) for chlorthalidone. All the treatments were well tolerated overall. Besides the slight increase in losartan C<sub>max</sub>, the combination therapy did not show clinically significant pharmacokinetic interactions in terms of systemic drug exposure.</AbstractText><CopyrightInformation>&#xa9; 2026, The American College of Clinical Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Seol Ju</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Center for Clinical Pharmacology and Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Jeonbuk National University College of Medicine, Jeonju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Sung Hee</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yirang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jae-Yong</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Hanmi Pharmaceutical Co., Ltd.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Drug Dev</MedlineTA><NlmUniqueID>101572899</NlmUniqueID><ISSNLinking>2160-763X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1J444QC288</RegistryNumber><NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance></Chemical><Chemical><RegistryNumber>JMS50MPO89</RegistryNumber><NameOfSubstance UI="D019808">Losartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q0MQD1073Q</RegistryNumber><NameOfSubstance UI="D002752">Chlorthalidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017311" MajorTopicYN="Y">Amlodipine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019808" MajorTopicYN="Y">Losartan</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002752" MajorTopicYN="Y">Chlorthalidone</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antihypertensive</Keyword><Keyword MajorTopicYN="N">pharmacokinetic interaction</Keyword><Keyword MajorTopicYN="N">phase I</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41549823</ArticleId><ArticleId IdType="doi">10.1002/cpdd.70024</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>World Health Organization Cardiovascular Diseases Fact Sheet. Accessed November 29, 2018. http://www.whoint/mediacentre/factsheets/fs317/en/</Citation></Reference><Reference><Citation>World Health Organization. A global brief on hypertension: Silent killer, global public health crisis, (WHO/DCO/WHD/2013.2). WHO; 2013.</Citation></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, et&#xa0;al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127&#x2010;e248.</Citation></Reference><Reference><Citation>James PA, Oparil S, Carter BL, et&#xa0;al. 2014 evidence&#x2010;based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507&#x2010;520.</Citation></Reference><Reference><Citation>Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta&#x2010;analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290&#x2010;300.</Citation></Reference><Reference><Citation>Product information: NORVASC&#xae; oral tablets, Amlodipine besylate oral tablets. Pfizer Labs; 2010.</Citation></Reference><Reference><Citation>Product information: Cozaar&#xae;, Losartan potassium tablets. Merck &amp; Co., Inc.; 2005.</Citation></Reference><Reference><Citation>Product information: Chlorthalidone&#xae;, Chlorthalidone tablet. Mylan Pharmaceuticals, Inc.; 2006.</Citation></Reference><Reference><Citation>Food and Drug Administration Center for Drugs Evaluation Research. Guidance for Industry: Hypertension: Developing Fixed&#x2010;Combination Drug Products for Treatment. 2018. FDA Maryland.</Citation></Reference><Reference><Citation>Choi Y, Lee S, Cho SM, et&#xa0;al. Comparisons of the pharmacokinetics and tolerability of fixed&#x2010;dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open&#x2010;label, single&#x2010;dose, two&#x2010;period, two&#x2010;sequence crossover study. Drug Des Devel Ther. 2016;10:3021&#x2010;3028.</Citation></Reference><Reference><Citation>Zhu Y, Wang F, Li Q, et&#xa0;al. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014;42(2):245&#x2010;249.</Citation></Reference><Reference><Citation>Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797&#x2010;814.</Citation></Reference><Reference><Citation>Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E&#x2010;3174. Eur J Clin Pharmacol. 1998;53(6):445&#x2010;449.</Citation></Reference><Reference><Citation>Williamson KM, Patterson JH, McQueen RH, Adams KF, Jr., Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1998;63(3):316&#x2010;323.</Citation></Reference><Reference><Citation>Bramlage P, Schmidt S, Sims H. Fixed&#x2010;dose vs free&#x2010;dose combinations for the management of hypertension&#x2010;An analysis of 81 958 patients. J Clin Hypertens. 2018;20(4):705&#x2010;715.</Citation></Reference><Reference><Citation>Hong SH, Wang J, Tang J. Dynamic view on affordability of fixed&#x2010;dose combination antihypertensive drug therapy. Am J Hypertens. 2013;26(7):879&#x2010;887.</Citation></Reference><Reference><Citation>Hong SJ, Jeong HS, Han SH, et&#xa0;al. Comparison of fixed&#x2010;dose combinations of amlodipine/losartan potassium/chlorthalidone and amlodipine/losartan potassium in patients with Stage 2 hypertension inadequately controlled with amlodipine/losartan potassium: a randomized, double&#x2010;blind, multicenter, phase III study. Clin Ther. 2017;39(10):2049&#x2010;2060.</Citation></Reference><Reference><Citation>Materson BJ, Oster JR, Michael UF, et&#xa0;al. Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose. Clin Pharmacol Ther. 1978;24(2):192&#x2010;8.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41549805</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2160-7648</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical pharmacology in drug development</Title><ISOAbbreviation>Clin Pharmacol Drug Dev</ISOAbbreviation></Journal><ArticleTitle>Effect of High-Fat Food on the Pharmacokinetics and Safety of Amlodipine/Benazepril in Healthy Chinese Participants.</ArticleTitle><Pagination><StartPage>e70022</StartPage><MedlinePgn>e70022</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpdd.70022</ELocationID><Abstract><AbstractText>This study assessed the effect of high-fat food on pharmacokinetics and safety of amlodipine, benazepril, and benazeprilat in healthy Chinese participants under fasting and fed conditions from a bioequivalence trial. This trial enrolled a total of 92 healthy participants, and there was a significant difference in age between fasting and fed trials (P =&#xa0;.006). These participants received an amlodipine/benazepril capsule containing 5&#xa0;mg amlodipine and 10&#xa0;mg benazepril each period with a 21-day washout under fasting or fed conditions. Twenty-four blood samples were obtained from baseline to 168&#xa0;h after drug administration for pharmacokinetic analyses. The plasma concentrations of amlodipine, benazepril, and benazeprilat were determined by a validated liquid chromatography-tandem mass spectrometry method. After controlling for age, analysis of covariance (ANCOVA) or Quade's ANCOVA of pharmacokinetic results indicated that a high-fat meal did not significantly influence the primary pharmacokinetic parameters of amlodipine, benazepril, and benazeprilat, except for the maximum plasma concentration (C<sub>max</sub>) and time to reach maximum plasma concentration (T<sub>max</sub>) for benazepril and benazeprilat. The high-fat food decreased C<sub>max</sub> of benazepril by 64.1% and C<sub>max</sub> of benazeprilat by 30.8%, and increased T<sub>max</sub> of benazepril by 408.2% and T<sub>max</sub> of benazeprilat by 167.8% The incidence of most frequently observed AE of hypotension was significantly different (P =&#xa0;.014, risk ratio = 2.286, and 95% confidence intervals 1.103 to 4.737) under fasting and fed conditions. It suggested that high-fat food containing 800 to 1000&#xa0;kcal might be the risk factor for healthy Chinese participants taking amlodipine/benazepril capsules.</AbstractText><CopyrightInformation>&#xa9; 2026, The American College of Clinical Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Congyang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Laboratory, Hebei General Hospital, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Haojing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Laboratory, Hebei General Hospital, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Laboratory, Hebei General Hospital, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Laboratory, Hebei General Hospital, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Caihui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Laboratory, Hebei General Hospital, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Wanjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Laboratory, Hebei General Hospital, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Huizhen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Laboratory, Hebei General Hospital, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Zhanjun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Laboratory, Hebei General Hospital, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Drug Dev</MedlineTA><NlmUniqueID>101572899</NlmUniqueID><ISSNLinking>2160-763X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1J444QC288</RegistryNumber><NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance></Chemical><Chemical><RegistryNumber>UDM7Q7QWP8</RegistryNumber><NameOfSubstance UI="C044946">benazepril</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Population" UI="C000724312">Chinese people</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017311" MajorTopicYN="Y">Amlodipine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001552" MajorTopicYN="Y">Benzazepines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="Y">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059305" MajorTopicYN="Y">Diet, High-Fat</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="N">Fasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018565" MajorTopicYN="Y">Food-Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N" AutoHM="Y">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amlodipine</Keyword><Keyword MajorTopicYN="N">benazepril</Keyword><Keyword MajorTopicYN="N">benazeprilat</Keyword><Keyword MajorTopicYN="N">high&#x2010;fat food</Keyword><Keyword MajorTopicYN="N">pharmacokinetic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41549805</ArticleId><ArticleId IdType="doi">10.1002/cpdd.70022</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>National Center for Cardiovascular Diseases, China. Report on cardiovascular health and diseases in China 2022. December 31, 2023. Accessed January 9, 2024. https://www.nccd.org.cn/Sites/Uploaded/File/2023/6/%E4%B8%AD%E5%9B%BD%E5%BF%83%E8%A1%80%E7%AE%A1%E5%81%A5%E5%BA%B7%E4%B8%8E%E7%96%BE%E7%97%85%E6%8A%A5%E5%91%8A2022.pdf</Citation></Reference><Reference><Citation>Guideline for the Pharmacological Treatment of Hypertension in Adults. World Health Organization; 2021. Accessed January 12, 2024. http://www.ncbi.nlm.nih.gov/books/NBK573631/</Citation></Reference><Reference><Citation>Jamerson K, Shi V. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high&#x2010;risk patients. N Engl J Med. 2008;359(23):2417&#x2010;2428.</Citation></Reference><Reference><Citation>Neutel JM, Smith DHG, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) Study. J Clin Hypertens. 2005;7(11):641&#x2010;646.</Citation></Reference><Reference><Citation>Reichek N, Devereux RB, Rocha RA, et&#xa0;al. Magnetic resonance imaging left ventricular mass reduction with fixed&#x2010;dose angiotensin&#x2010;converting enzyme inhibitor&#x2013;based regimens in patients with high&#x2010;risk hypertension. Hypertension. 2009;54(4):731&#x2010;737.</Citation></Reference><Reference><Citation>Bakris GL, Sarafidis PA, Weir MR, et&#xa0;al. Renal outcomes with different fixed&#x2010;dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173&#x2010;1181.</Citation></Reference><Reference><Citation>Chrysant SG. The role of angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Am J Cardiovasc Drugs. 2010;10(5):315&#x2010;320.</Citation></Reference><Reference><Citation>Makani H, Bangalore S, Romero J, Wever&#x2010;Pinzon O, Messerli FH. Effect of renin&#x2010;angiotensin system blockade on calcium channel blocker&#x2010;associated peripheral edema. Am J Med. 2011;124(2):128&#x2010;135.</Citation></Reference><Reference><Citation>Mallat S, Tanios BY, Itani HS. Current perspectives on combination therapy in the management of hypertension. Integr Blood Press Control. 2013;6:69&#x2010;78.</Citation></Reference><Reference><Citation>Koziolek M, Alcaro S, Augustijns P, et&#xa0;al. The mechanisms of pharmacokinetic food&#x2010;drug interactions &#x2013; a perspective from the UNGAP group. Eur J Pharm Sci. 2019;134:31&#x2010;59.</Citation></Reference><Reference><Citation>Sun JX, Cipriano A, Chan K, John VA. Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. Eur J Clin Pharmacol. 1994;47(3):285&#x2010;289.</Citation></Reference><Reference><Citation>Chung M, Calcagni A, Glue P, Bramson C. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol. 2006;46(10):1212&#x2010;1216.</Citation></Reference><Reference><Citation>Sunkara G, Jiang X, Reynolds C, et&#xa0;al. Effect of food on the oral bioavailability of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide fixed dose combination tablets in healthy subjects. Clin Pharmacol Drug Dev. 2014;3(6):487&#x2010;492.</Citation></Reference><Reference><Citation>Chen B, Chen Z, Lv D, Sun Y, Chen H. Pharmacokinetics, bioequivalence, and safety studies of amlodipine besylate in healthy subjects. Clin Pharmacol Drug Dev. 2022;11(6):717&#x2010;723.</Citation></Reference><Reference><Citation>U. S. Food and Drug Administration. Full Prescribing information of LOTREL (amlodipine and benazepril hydrochloride) capsules. April 21, 2021. Accessed December 29, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020364Orig1s068lbl.pdf</Citation></Reference><Reference><Citation>Health Canada. Benazepril product monograph. December 2, 2019. Accessed March 26, 2024. https://pdf.hres.ca/dpd_pm/00054195.PDF</Citation></Reference><Reference><Citation>Health Canada. Amlodipine product monograph. September 21, 2023. Accessed March 26, 2024. https://pdf.hres.ca/dpd_pm/00072734.PDF</Citation></Reference><Reference><Citation>Chien KL, Chao CL, Su TC. Bioavailability study of fixed&#x2010;dose tablet versus capsule formulation of amlodipine plus benazepril: a randomized, single&#x2010;dose, two&#x2010;sequence, two&#x2010;period, open&#x2010;label, crossover study in healthy volunteers. Curr Ther Res Clin Exp. 2005;66(2):69&#x2010;79.</Citation></Reference><Reference><Citation>Hauschke D, Steinijans VW, Diletti E, Burke M. Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm. 1992;20(5):557&#x2010;561.</Citation></Reference><Reference><Citation>Wang T, Wang Y, Lin S, et&#xa0;al. Evaluation of pharmacokinetics and safety with bioequivalence of amlodipine in healthy Chinese volunteers: bioequivalence study findings. J Clin Lab Anal. 2020;34(6):e23228.</Citation></Reference><Reference><Citation>Song H, Qiu B, Sun X, et&#xa0;al. Bioequivalence study of single&#x2010;pill capsule formulation of amlodipine plus benazepril in healthy Chinese subjects under fasting and fed conditions. Drug Des Devel Ther. 2025;19:1853&#x2010;1868.</Citation></Reference><Reference><Citation>Lv C, Wei C, Wang X, et&#xa0;al. The influence of food on the pharmacokinetics of amlodipine and losartan after single&#x2010;dose of its compound tablets in healthy Chinese subjects. Drug Res. 2014;64(5):229&#x2010;235.</Citation></Reference><Reference><Citation>Kaiser G, Ackermann R, Dieterle W, et&#xa0;al. Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. Eur J Clin Pharmacol. 1990;38(4):379&#x2010;385.</Citation></Reference><Reference><Citation>Macdonald N, Elliott H, Hughes D, Reid J. A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril. Br J Clin Pharmacol. 1993;36(3):201&#x2010;204.</Citation></Reference><Reference><Citation>Fadda HM, McConnell EL, Short MD, Basit AW. Meal&#x2010;induced acceleration of tablet transit through the human small intestine. Pharm Res. 2009;26(2):356&#x2010;360.</Citation></Reference><Reference><Citation>Kn&#xfc;tter I, Wollesky C, Kottra G, et&#xa0;al. Transport of angiotensin&#x2010;converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008;372(2):432&#x2010;441.</Citation></Reference><Reference><Citation>Koven W, Schulte P. The effect of fasting and refeeding on mRNA expression of PepT1 and gastrointestinal hormones regulating digestion and food intake in zebrafish (Danio rerio). Fish Physiol Biochem. 2012;38(6):1565&#x2010;1575.</Citation></Reference><Reference><Citation>N&#xe4;ssl AM, Rubio&#x2010;Aliaga I, Sailer M, Daniel H. The intestinal peptide transporter PEPT1 is involved in food intake regulation in mice fed a high&#x2010;protein diet. PLoS ONE. 2011;6(10):e26407.</Citation></Reference><Reference><Citation>Gengo F, Brady E. The pharmacokinetics of benazepril relative to other ace inhibitors. Clin Cardiol. 1991;14(8 Suppl 4):IV44&#x2010;50; discussion IV51&#x2010;5.</Citation></Reference><Reference><Citation>Khalifa MKA, Salem HA, Shawky SM, Eassa HA, Elaidy AM. Enhancement of zaleplon oral bioavailability using optimized self&#x2010;nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients. Drug Deliv. 2019;26(1):1243&#x2010;1253.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. Assessing the effects of food on drugs in INDs and NDAs &#x2014; clinical pharmacology considerations. June 2022. Accessed November 26, 2025. https://www.fda.gov/media/121313/download</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. Generic drugs. March 13, 2025. Accessed November 27, 2025. https://www.fda.gov/drugs/buying&#x2010;using&#x2010;medicine&#x2010;safely/generic&#x2010;drugs</Citation></Reference><Reference><Citation>Chan AW, Tetzlaff JM, G&#xf8;tzsche PC, et&#xa0;al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.</Citation></Reference><Reference><Citation>Rothman KJ. A potential bias in safety evaluation during open&#x2010;label extensions of randomized clinical trials. Pharmacoepidemiol Drug Saf. 2004;13(5):295&#x2010;298.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41513010</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0720</ISSN><JournalIssue CitedMedium="Internet"><Volume>218</Volume><PubDate><Year>2026</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</Title><ISOAbbreviation>Eur J Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>Assembled fixed-dose combination tablet for hypertension: A modular design inspired by LEGO&#xae; architecture.</ArticleTitle><Pagination><StartPage>107430</StartPage><MedlinePgn>107430</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejps.2026.107430</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0928-0987(26)00004-7</ELocationID><Abstract><AbstractText>Polypharmacy in chronic diseases like hypertension often compromises patient adherence and therapeutic success due to complex regimens. While conventional fixed-dose combination (FDC) tablets improve adherence, they lack the dose flexibility needed for personalized treatment. This study addresses this gap by developing and characterizing a novel, LEGO&#xae;-inspired assemblable FDC tablet system for customizable antihypertensive therapy. Using 3D-printed molds, individual, stackable modules containing either Amlodipine, Valsartan, or Hydrochlorothiazide (HCTZ) were created. The study evaluated two polymer matrices, revealing a critical dependence on the active pharmaceutical ingredient (API). Gelatin-based matrices were effective for Amlodipine and Valsartan, achieving rapid drug with USP dissolution standards; however, this matrix was incompatible release (&gt;90% within 30 min) compliant with HCTZ. Conversely, an HPMC-based matrix successfully formulated HCTZ with a controlled-release profile but was unsuitable for the other two drugs. This work validates the proof-of-concept for a modular FDC system as a promising platform for personalized polypharmacy. However, it also highlights that achieving desired drug release profiles requires careful, API-specific polymer selection, presenting a key formulation challenge for this innovative approach.</AbstractText><CopyrightInformation>Copyright &#xa9; 2026 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sangnim</LastName><ForeName>Tanikan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, 20131, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwanpitak</LastName><ForeName>Kittipat</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, 20131, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sriamornsak</LastName><ForeName>Pornsak</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand; Academy of Science, The Royal Society of Thailand, Bangkok, 10300, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huanbutta</LastName><ForeName>Kampanart</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Manufacturing Pharmacy, College of Pharmacy, Rangsit University, Pathum Thani, 12000, Thailand. Electronic address: Kampanart.h@rsu.ac.th.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharm Sci</MedlineTA><NlmUniqueID>9317982</NlmUniqueID><ISSNLinking>0928-0987</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0J48LPH2TH</RegistryNumber><NameOfSubstance UI="D006852">Hydrochlorothiazide</NameOfSubstance></Chemical><Chemical><RegistryNumber>1J444QC288</RegistryNumber><NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>80M03YXJ7I</RegistryNumber><NameOfSubstance UI="D000068756">Valsartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>9000-70-8</RegistryNumber><NameOfSubstance UI="D005780">Gelatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006852" MajorTopicYN="N">Hydrochlorothiazide</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017311" MajorTopicYN="N">Amlodipine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068756" MajorTopicYN="N">Valsartan</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066330" MajorTopicYN="N">Printing, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005780" MajorTopicYN="N">Gelatin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3d printing</Keyword><Keyword MajorTopicYN="N">Fixed-dose combination (FDC)</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword><Keyword MajorTopicYN="N">Modular drug delivery</Keyword><Keyword MajorTopicYN="N">Personalized medicine</Keyword><Keyword MajorTopicYN="N">Polypharmacy</Keyword></KeywordList><CoiStatement>Declaration of competing interest All authors (T. Sangnim, K. Suwanpitak, P. Sriamornsak, and K. Huanbutta) declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>14</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>10</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>9</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41513010</ArticleId><ArticleId IdType="doi">10.1016/j.ejps.2026.107430</ArticleId><ArticleId IdType="pii">S0928-0987(26)00004-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41478551</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3476</ISSN><JournalIssue CitedMedium="Internet"><Volume>690</Volume><PubDate><Year>2026</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>International journal of pharmaceutics</Title><ISOAbbreviation>Int J Pharm</ISOAbbreviation></Journal><ArticleTitle>Fabrication and characterization of taste-masked core-shell nanofibre mats for dual drug delivery of antihypertensives in pediatrics.</ArticleTitle><Pagination><StartPage>126541</StartPage><MedlinePgn>126541</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2025.126541</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-5173(25)01378-X</ELocationID><Abstract><AbstractText>Drug adherence in pediatrics can be challenging due to bitter drug taste, dysphagia and polypharmacy. With pediatric hypertension on the rise worldwide, this study investigated the use of electrospinning to create a novel taste-masked, fixed-dose combination of lisinopril dihydrate (LIS) and amlodipine besylate (AML) for paediatric use. Electrospun nanofibres of the antihypertensives were formulated as core-shell fibres with polyvinylpyrrolidone (PVP), and Eudragit&#xae; EPO (EEPO) by applying an electrical charge to a viscous mixture of the drugs, polymers and solvents. The drug loading, release kinetics, morphology, thermal analysis, physical and solid-state characterization of the fibre mats were evaluated. Taste-masking was investigated in vitro by electronic-tongue analysis. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) analyses showed smooth, non-beaded core-shell fibres with diameters in the nanorange. Fourier transform infra-red (FTIR) spectroscopy and x-ray diffraction (XRD) studies confirmed the drugs were amorphously dispersed within the fibres and thermal analysis studies showed acceptable stability profile of the formulations. Both drugs were over 90&#xa0;% released in 15 mins consistent with immediate release formulations. The e-tongue mean sensor response plot showed the nanofibre mats achieved a statistically significant enhanced taste-masking (p&#xa0;&lt;&#xa0;0.0001) compared to raw amlodipine which registered a high bitterness reading of 87&#xa0;mV. This study therefore indicates that coaxial electrospinning may be used to produce a fixed-dose taste masked nanofibre mat of LIS and AML that can potentially be used to improve adherence in children.</AbstractText><CopyrightInformation>Copyright &#xa9; 2026 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ubani-Ukoma</LastName><ForeName>Uloma N</ForeName><Initials>UN</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University College London (UCL), 29-39 Brunswick Square, WC1N 1AX London, United Kingdom. Electronic address: uubani-ukoma@unilag.edu.ng.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiunan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University College London (UCL), 29-39 Brunswick Square, WC1N 1AX London, United Kingdom. Electronic address: li.yuki.xiunan@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faiyaz</LastName><ForeName>Mahmood</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University College London (UCL), 29-39 Brunswick Square, WC1N 1AX London, United Kingdom. Electronic address: faiyaz.mahmood.21@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parhizkar</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University College London (UCL), 29-39 Brunswick Square, WC1N 1AX London, United Kingdom. Electronic address: maryam.parhizkar@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Duncan Q M</ForeName><Initials>DQM</Initials><AffiliationInfo><Affiliation>Faculty of Science, University of Bath, Bath BA2 7AY, United Kingdom. Electronic address: dqmc21@bath.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelhakim</LastName><ForeName>Hend E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Global Business School for Health, UCL, 7 Sidings St, E20 2AE London, United Kingdom. Electronic address: hend.abdelhakim@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Pharm</MedlineTA><NlmUniqueID>7804127</NlmUniqueID><ISSNLinking>0378-5173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1J444QC288</RegistryNumber><NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance></Chemical><Chemical><RegistryNumber>E7199S1YWR</RegistryNumber><NameOfSubstance UI="D017706">Lisinopril</NameOfSubstance></Chemical><Chemical><RegistryNumber>FZ989GH94E</RegistryNumber><NameOfSubstance UI="D011205">Povidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>905HNO1SIH</RegistryNumber><NameOfSubstance UI="C518398">Eudragit E PO</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011109">Polymethacrylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057139" MajorTopicYN="Y">Nanofibers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013649" MajorTopicYN="Y">Taste</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017311" MajorTopicYN="Y">Amlodipine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017706" MajorTopicYN="Y">Lisinopril</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011205" MajorTopicYN="N">Povidone</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011109" MajorTopicYN="N">Polymethacrylic Acids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antihypertensives</Keyword><Keyword MajorTopicYN="N">Drug adherence</Keyword><Keyword MajorTopicYN="N">Electrospinning</Keyword><Keyword MajorTopicYN="N">Fixed-dose combination</Keyword><Keyword MajorTopicYN="N">Nanofibres</Keyword><Keyword MajorTopicYN="N">Pediatrics</Keyword><Keyword MajorTopicYN="N">Taste-masking</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>5</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>1</Day><Hour>19</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41478551</ArticleId><ArticleId IdType="doi">10.1016/j.ijpharm.2025.126541</ArticleId><ArticleId IdType="pii">S0378-5173(25)01378-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41436901</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1918</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>2</Issue><PubDate><Year>2026</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical drug investigation</Title><ISOAbbreviation>Clin Drug Investig</ISOAbbreviation></Journal><ArticleTitle>Population Pharmacokinetics of Amlodipine and Telmisartan Following Oral Administration of a Single-Pill Fixed-Dose Combination in Healthy Korean Male Subjects.</ArticleTitle><Pagination><StartPage>159</StartPage><EndPage>172</EndPage><MedlinePgn>159-172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40261-025-01513-z</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">Fixed-dose combinations (FDCs) of amlodipine and telmisartan are widely used for hypertension management owing to their efficacy and improved adherence. This study aimed to characterize the pharmacokinetics (PKs) of both drugs after a single oral dose of a single-pill FDC of amlodipine 5 mg/telmisartan 80 mg in healthy Korean males.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 681 amlodipine and 1500 telmisartan plasma concentrations from 32 healthy Korean males were retrospectively obtained from a bioequivalence study. Noncompartmental analysis and population analysis were conducted using WinNonLin&#x2122; (Pharsight Corp., Mountain View, CA, USA) and NONMEM<sup>&#xae;</sup> (ICON Development Solutions, Hanover, MD, USA), respectively. A two-compartment model with first-order absorption and elimination was selected for both drugs. Covariate screening using a stepwise approach evaluated 38 demographic and clinical factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Amlodipine exhibited a longer half-life and a larger apparent volume of distribution than telmisartan. Telmisartan PKs showed high interindividual (45.9% for absorption rate constant, 45.3% for apparent volume of distribution of the central compartment [V<sub>1</sub>/F], and 40.9% for apparent clearance [CL/F]), interoccasion (53.7% for V<sub>1</sub>/F), and residual (80.3%) variabilities. Preliminary covariate analysis suggested that body surface area and age potentially influenced V<sub>1</sub>/F and CL/F for amlodipine, while height, smoking status, and total bilirubin levels were associated with telmisartan V<sub>1</sub>/F and CL/F.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">To our knowledge, this is the first population PK study to characterize the PKs of amlodipine and telmisartan co-administered as a single-pill FDC and to identify preliminary covariates that may influence their PK profiles.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yu</LastName><ForeName>Eunji</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Kyungsung University, 309 Suyeong-ro, Nam-gu, Busan, 48434, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hwang</LastName><ForeName>Hee Kyung</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Daewoo Pharm Co., Ltd., 153 Dadae-ro, Saha-gu, Busan, 49393, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy and Research Institute for Drug Development, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan, 46241, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Bo Ram</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Daewoo Pharm Co., Ltd., 153 Dadae-ro, Saha-gu, Busan, 49393, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy and Research Institute for Drug Development, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan, 46241, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyo Cheol</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Daewoo Pharm Co., Ltd., 153 Dadae-ro, Saha-gu, Busan, 49393, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy and Research Institute for Drug Development, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan, 46241, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Seh Hyon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Kyungsung University, 309 Suyeong-ro, Nam-gu, Busan, 48434, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Woojin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Senior Health Convergence Research Center, Chungnam National University, Daejeon, 34134, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staatz</LastName><ForeName>Christine E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0002-4595-9376</Identifier><AffiliationInfo><Affiliation>School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Dutton Park, Brisbane, QLD, 4102, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min-Soo</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Research Institute for Drug Development, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan, 46241, Republic of Korea. minsookim@pusan.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>In-Hwan</ForeName><Initials>IH</Initials><Identifier Source="ORCID">0000-0002-9538-0565</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Kyungsung University, 309 Suyeong-ro, Nam-gu, Busan, 48434, Republic of Korea. baek@ks.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Dutton Park, Brisbane, QLD, 4102, Australia. baek@ks.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Functional Food and Drug Convergence Research Center, Industry-Academic Cooperation Foundation, Kyungsung University, 309, Suyeong-ro, Nam-gu, Busan, 48434, Republic of Korea. baek@ks.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RS-2025-16066707</GrantID><Agency>Ministry of Science and ICT, South Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Drug Investig</MedlineTA><NlmUniqueID>9504817</NlmUniqueID><ISSNLinking>1173-2563</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1J444QC288</RegistryNumber><NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance></Chemical><Chemical><RegistryNumber>U5SYW473RQ</RegistryNumber><NameOfSubstance UI="D000077333">Telmisartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001565">Benzoates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017311" MajorTopicYN="Y">Amlodipine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077333" MajorTopicYN="N">Telmisartan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="Y">Benzimidazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001565" MajorTopicYN="Y">Benzoates</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declarations. Conflict of interest: Hee Kyung Hwang, Bo Ram Kim, and Hyo Cheol Kim are employees of Daewoo Pharm Co., Ltd. Christine Staatz is an Editorial Board member of Clinical Drug Investigation. Christine Staatz was not involved in the selection of peer reviewers for this manuscript nor in any of the subsequent editorial decisions. The other authors have no competing interests to declare that are relevant to the content of this article. Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Ethics approval: The study protocol was approved by the Institutional Review Board of H-plus Yangji Hospital (approval no. HYJ 2021-05-001) and was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and the Korean Good Clinical Practice guidelines. Code availability: The model code that supports the findings of this study is available from the corresponding author upon reasonable request. Consent to participate: All participants provided written informed consent prior to enrollment in the original bioequivalence study. As this population pharmacokinetic analysis was conducted using de-identified data obtained from that completed study, additional informed consent was not required. Consent for publication: Not applicable. Author contributions: Eunji Yu: Data curation, formal analysis, investigation, methodology, and writing&#x2014;original draft. Hee Kyung Hwang: Conceptualization, data curation, formal analysis, investigation, methodology, and writing&#x2014;original draft. Bo Ram Kim: Data curation, formal analysis, validation, and writing&#x2014;review and editing. Hyo Cheol Kim: Data curation, validation, and writing&#x2014;review and editing. Christine E. Staatz: Investigation, methodology, supervision, validation, and writing&#x2014;review and editing. Seh-Hyon Song: Conceptualization, formal analysis, and writing&#x2014;review and editing. Woojin Jung: Formal analysis, investigation, methodology, validation, and writing&#x2014;review and editing. Min-Soo Kim: Conceptualization, formal analysis, supervision, and writing&#x2014;review and editing. In-hwan Baek: Conceptualization, funding acquisition, investigation, methodology, and writing&#x2014;original draft supervision. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>24</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>23</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41436901</ArticleId><ArticleId IdType="doi">10.1007/s40261-025-01513-z</ArticleId><ArticleId IdType="pii">10.1007/s40261-025-01513-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016. https://doi.org/10.1161/CIRCULATIONAHA.115.018912 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.018912</ArticleId><ArticleId IdType="pubmed">28034899</ArticleId><ArticleId IdType="pmc">4979614</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021&#x2013;104. https://doi.org/10.1093/eurheartj/ehy339 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy339</ArticleId><ArticleId IdType="pubmed">30165516</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018. https://doi.org/10.1161/HYP.0000000000000066 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYP.0000000000000066</ArticleId><ArticleId IdType="pubmed">29785961</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024. https://doi.org/10.1093/eurheartj/ehae178 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae178</ArticleId><ArticleId IdType="pubmed">39412133</ArticleId><ArticleId IdType="pmc">11458150</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JG, Palmer BF, Vogel Anderson K, Sever P. Amlodipine in the current management of hypertension. J Clin Hypertens (Greenwich). 2023. https://doi.org/10.1111/jch.14709 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jch.14709</ArticleId><ArticleId IdType="pubmed">38133535</ArticleId></ArticleIdList></Reference><Reference><Citation>Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, et al. Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother. 2011. https://doi.org/10.1517/14656566.2011.632367 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2011.632367</ArticleId><ArticleId IdType="pubmed">22077832</ArticleId></ArticleIdList></Reference><Reference><Citation>Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024;171:116169. https://doi.org/10.1016/j.biopha.2024.116169 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2024.116169</ArticleId><ArticleId IdType="pubmed">38228033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothlin RP, Pelorosso FG, Duarte M, Nicolosi L, Ignacio FC, Salgado MV, et al. Telmisartan and losartan: the marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19. Pharmacol Res Perspect. 2023;11(2):e01083. https://doi.org/10.1002/prp2.1083 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.1083</ArticleId><ArticleId IdType="pubmed">37038324</ArticleId><ArticleId IdType="pmc">10086312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011. https://doi.org/10.1111/j.1751-7176.2010.00397.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-7176.2010.00397.x</ArticleId><ArticleId IdType="pubmed">21366845</ArticleId></ArticleIdList></Reference><Reference><Citation>Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692&#x2013;705. https://doi.org/10.1161/HYPERTENSIONAHA.120.15781 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15781</ArticleId><ArticleId IdType="pubmed">33390044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjeldsen SE, Weber M, Oparil S, Jamerson KA. Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. Blood Press. 2008;17(5&#x2013;6):260&#x2013;9. https://doi.org/10.1080/08037050802565171 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08037050802565171</ArticleId><ArticleId IdType="pubmed">19061055</ArticleId></ArticleIdList></Reference><Reference><Citation>Farag SM, Rabea HM, Abdelrahim ME, Mahmoud HB. Target blood pressure and combination therapy: focus on angiotensin receptor blockers combination with either calcium channel blockers or beta blockers. Curr Hypertens Rev. 2022;18(2):138&#x2013;44. https://doi.org/10.2174/1573402118666220627120254 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573402118666220627120254</ArticleId><ArticleId IdType="pubmed">36508272</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlejohn TW, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich). 2009;11(4):207&#x2013;13. https://doi.org/10.1111/j.1751-7176.2009.00098.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-7176.2009.00098.x</ArticleId><ArticleId IdType="pubmed">19614805</ArticleId></ArticleIdList></Reference><Reference><Citation>Moen MD. Telmisartan/amlodipine. Am J Cardiovasc Drugs. 2010;10(6):401&#x2013;12. https://doi.org/10.2165/11204880-000000000-00000 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11204880-000000000-00000</ArticleId><ArticleId IdType="pubmed">21090832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B-J, Cho K-I, Kwon HM, Choi S-M, Yoon C-H, Lim SW, et al. Effect of a fixed-dose combination of telmisartan/S-amlodipine on circadian blood pressure compared with telmisartan monotherapy: TENUVA-BP study. Clin Hypertens. 2022;28(1):7. https://doi.org/10.1186/s40885-021-00184-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-021-00184-0</ArticleId><ArticleId IdType="pubmed">35227313</ArticleId><ArticleId IdType="pmc">8886760</ArticleId></ArticleIdList></Reference><Reference><Citation>Abernethy DR. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology. 1992;80(1):31&#x2013;6. https://doi.org/10.1159/000175050 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000175050</ArticleId><ArticleId IdType="pubmed">1534713</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986;22(1):21&#x2013;5. https://doi.org/10.1111/j.1365-2125.1986.tb02874.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1986.tb02874.x</ArticleId><ArticleId IdType="pubmed">2943308</ArticleId><ArticleId IdType="pmc">1401071</ArticleId></ArticleIdList></Reference><Reference><Citation>Fares H, DiNicolantonio JJ, O&#x2019;Keefe JH, Lavie CJ. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016;3(2):e000473. https://doi.org/10.1136/openhrt-2016-000473 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2016-000473</ArticleId><ArticleId IdType="pubmed">27752334</ArticleId><ArticleId IdType="pmc">5051471</ArticleId></ArticleIdList></Reference><Reference><Citation>Rognstad S, S&#xf8;raas CL, Brunborg C, Halvorsen LV, Brobak KM, Olsen E, et al. Pharmacokinetic variability of amlodipine serum concentration and effect on blood pressure in patients treated for hypertension. Pharmacol Res Perspect. 2025;13(4):e70140. https://doi.org/10.1002/prp2.70140 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.70140</ArticleId><ArticleId IdType="pubmed">40616336</ArticleId><ArticleId IdType="pmc">12227894</ArticleId></ArticleIdList></Reference><Reference><Citation>Deppe S, B&#xf6;ger RH, Weiss J, Benndorf RA. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol. 2010;6(7):863&#x2013;71. https://doi.org/10.1517/17425255.2010.494597 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425255.2010.494597</ArticleId><ArticleId IdType="pubmed">20509777</ArticleId></ArticleIdList></Reference><Reference><Citation>Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs. 2006;66(1):51&#x2013;83. https://doi.org/10.2165/00003495-200666010-00004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200666010-00004</ArticleId><ArticleId IdType="pubmed">16398568</ArticleId></ArticleIdList></Reference><Reference><Citation>Romodanovskii D, Goryachev D, Khokhlov A, Miroshnikov A. Investigation planning and bioequivalence evaluation of angiotensin II receptor antagonists. Pharm Chem J. 2019;53:680&#x2013;4. https://doi.org/10.1007/s11094-019-02062-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11094-019-02062-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh Y-H, Lim H-S, Kim MJ, Kim YH, Choi HY, Sung HR, et al. Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Clin Ther. 2012;34(7):1625&#x2013;35. https://doi.org/10.1016/j.clinthera.2012.05.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2012.05.010</ArticleId><ArticleId IdType="pubmed">22721873</ArticleId></ArticleIdList></Reference><Reference><Citation>Stangier J, Su CAP. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40(12):1347&#x2013;54. https://doi.org/10.1177/009127000004001206 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/009127000004001206</ArticleId><ArticleId IdType="pubmed">11185633</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang WY, Seong SJ, Ohk B, Gwon M-R, Kim BK, La S, et al. Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. Drug Des Dev Ther. 2018;12:545&#x2013;53. https://doi.org/10.2147/DDDT.S156492 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S156492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorain B, Choudhury H, Halder D, Sarkar AK, Sarkar P, Biswas E, et al. A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. Drug Res (Stuttg). 2013;63(4):177&#x2013;84. https://doi.org/10.1055/s-0033-1334882 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0033-1334882</ArticleId><ArticleId IdType="pubmed">23471702</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh M, Park SE, Ghim JL, Choi YK, Shim EJ, Shin JG, et al. Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers. Drug Des Dev Ther. 2017;11:3543&#x2013;50. https://doi.org/10.2147/DDDT.S148534 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S148534</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon SJ, Jeon JY, Jang K, Yu KS, Lim Y, Kim MG. Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects. Drug Des Dev Ther. 2019;13:2533&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S210364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). Guideline for the Drug Equivalence Test. Bioequivalence Evaluation Division, Notice No. 2023-52; August 9, 2023 (revised). Osong: Ministry of Food and Drug Safety; 2023.</Citation></Reference><Reference><Citation>US Food and Drug Administration. Bioanalytical method validation: guidance for industry. Rockville: US FDA; 2018. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf . Accessed 20 Oct 2025.</Citation></Reference><Reference><Citation>Keizer RJ, Karlsson M, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometr Syst Pharmacol. 2013;2(6):e50. https://doi.org/10.1038/psp.2013.24 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/psp.2013.24</ArticleId></ArticleIdList></Reference><Reference><Citation>Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35(2):185&#x2013;202. https://doi.org/10.1007/s10928-007-9081-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10928-007-9081-1</ArticleId><ArticleId IdType="pubmed">18197467</ArticleId><ArticleId IdType="pmc">2798054</ArticleId></ArticleIdList></Reference><Reference><Citation>Baverel PG, Savic RM, Karlsson MO. Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2011;38(1):63&#x2013;82. https://doi.org/10.1007/s10928-010-9177-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10928-010-9177-x</ArticleId><ArticleId IdType="pubmed">21076858</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M, Huang J, Chen Y, Jin Q, Jiang H, Shi C, et al. Pharmacokinetics and bioequivalence of two fixed-dose combination tablets of valsartan/amlodipine (80/5 Mg) in healthy Chinese subjects. Drug Des Dev Ther. 2025;19:11&#x2013;22. https://doi.org/10.2147/DDDT.S485851 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S485851</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Wang Y, Chen R, He Y, Liu Y, Wang N, et al. Pharmacokinetics and bioequivalence of amlodipine besylate tablet in healthy Chinese volunteers under fasting and fed conditions. Clin Pharmacol Drug Dev. 2024;13(3):259&#x2013;64. https://doi.org/10.1002/cpdd.1345 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.1345</ArticleId><ArticleId IdType="pubmed">37997527</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong IH, Ryu S, Han N, Staatz CE, Baek IH. Population pharmacokinetics of telmisartan in healthy subjects and hypertensive patients. Clin Pharmacokinet. 2025;64(2):285&#x2013;95. https://doi.org/10.1007/s40262-024-01471-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-024-01471-3</ArticleId><ArticleId IdType="pubmed">39808372</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchitani T, Tomaru A, Aoki Y, Ishiguro N, Tsuda Y, Sugiyama Y. Elucidating nonlinear pharmacokinetics of telmisartan: integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model. CPT Pharmacometr Syst Pharmacol. 2024;13(7):1224&#x2013;37. https://doi.org/10.1002/psp4.13154 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.13154</ArticleId></ArticleIdList></Reference><Reference><Citation>Son H, Lee D, Lim LA, Jang SB, Roh H, Park K. Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. Drug Metab Pharmacokinet. 2014;29(2):120&#x2013;8. https://doi.org/10.2133/dmpk.dmpk-13-rg-053 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2133/dmpk.dmpk-13-rg-053</ArticleId><ArticleId IdType="pubmed">23965645</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan JL, Kogutt BK, Meek C, Stehel EK, McIntire DD, Sheffield JS, et al. Pharmacokinetics of amlodipine besylate at delivery and during lactation. Pregnancy Hypertens. 2018;11:77&#x2013;80. https://doi.org/10.1016/j.preghy.2018.01.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preghy.2018.01.002</ArticleId><ArticleId IdType="pubmed">29523279</ArticleId><ArticleId IdType="pmc">5846630</ArticleId></ArticleIdList></Reference><Reference><Citation>Courlet P, Guidi M, Alves Saldanha S, Cavassini M, Stoeckle M, Buclin T, et al. Population pharmacokinetic modelling to quantify the magnitude of drug&#x2013;drug interactions between amlodipine and antiretroviral drugs. Eur J Clin Pharmacol. 2021;77(7):979&#x2013;87. https://doi.org/10.1007/s00228-020-03060-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-020-03060-2</ArticleId><ArticleId IdType="pubmed">33452585</ArticleId><ArticleId IdType="pmc">8184532</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn JT, Nahata MC, Mahan Jr, Portman RJ. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006;46(8):905&#x2013;16. https://doi.org/10.1177/0091270006289844 . (Investigators P-).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270006289844</ArticleId><ArticleId IdType="pubmed">16855075</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatami S, Sarashina A, Yamamura N, Igarashi T, Tanigawara Y. Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients. Drug Metab Pharmacokinet. 2003;18(3):203&#x2013;11. https://doi.org/10.2133/dmpk.18.203 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2133/dmpk.18.203</ArticleId><ArticleId IdType="pubmed">15618736</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatami S, Yamamura N, Sarashina A, Yong CL, Igarashi T, Tanigawara Y. Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. Drug Metab Pharmacokinet. 2004;19(1):15&#x2013;23. https://doi.org/10.2133/dmpk.19.15 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2133/dmpk.19.15</ArticleId><ArticleId IdType="pubmed">15499165</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei Q, Yang L, Tan HY, Liu SK, Liu Y, Huang L, et al. Effects of genetic variants in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, ORM1 on PK/PD of telmisartan in Chinese patients with mild to moderate essential hypertension. Int J Clin Pharmacol Ther. 2017;55(8):659&#x2013;65. https://doi.org/10.5414/CP202744 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CP202744</ArticleId><ArticleId IdType="pubmed">28518053</ArticleId></ArticleIdList></Reference><Reference><Citation>Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119&#x2013;33. https://doi.org/10.1111/j.1365-2125.2004.02157.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2004.02157.x</ArticleId><ArticleId IdType="pubmed">15255794</ArticleId><ArticleId IdType="pmc">1884581</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooksbank JA, Greene SJ, DeWald TA, Mentz RJ. Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. Trends Cardiovasc Med. 2021;31(2):111&#x2013;6. https://doi.org/10.1016/j.tcm.2019.12.011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2019.12.011</ArticleId><ArticleId IdType="pubmed">32008834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayyed K, Le Vee M, Abdel-Razzak Z, Fardel O. Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017;44:27&#x2013;35. https://doi.org/10.1016/j.tiv.2017.06.014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tiv.2017.06.014</ArticleId><ArticleId IdType="pubmed">28629854</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano M, Naka R, Sasaki Y, Nishimoto S, Yumoto R. Effect of cigarette smoke extract on P-glycoprotein function in primary cultured and newly developed alveolar epithelial cells. Drug Metab Pharmacokinet. 2016;31(6):417&#x2013;24. https://doi.org/10.1016/j.dmpk.2016.08.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dmpk.2016.08.006</ArticleId><ArticleId IdType="pubmed">27836711</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerici M, Colombo G, Secundo F, Gagliano N, Colombo R, Portinaro N, et al. Cigarette smoke induces alterations in the drug-binding properties of human serum albumin. Blood Cells Mol Dis. 2014;52(4):166&#x2013;74. https://doi.org/10.1016/j.bcmd.2013.12.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcmd.2013.12.001</ArticleId><ArticleId IdType="pubmed">24388826</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44(1):33&#x2013;60. https://doi.org/10.2165/00003088-200544010-00002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200544010-00002</ArticleId><ArticleId IdType="pubmed">15634031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirvensalo P, Tornio A, Launiainen T, Paile-Hyv&#xe4;rinen M, Tapaninen T, Neuvonen M, et al. UGT1A3 and sex are major determinants of telmisartan pharmacokinetics&#x2014;a comprehensive pharmacogenomic study. Clin Pharmacol Ther. 2020;108(4):885&#x2013;95. https://doi.org/10.1002/cpt.1928 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1928</ArticleId><ArticleId IdType="pubmed">32498119</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohatagi S, Carrothers TJ, Kshirsagar S, Khariton T, Lee J, Salazar D. Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. J Clin Pharmacol. 2008;48(7):823&#x2013;36. https://doi.org/10.1177/0091270008317847 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270008317847</ArticleId><ArticleId IdType="pubmed">18490496</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41390557</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>13</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetic and bioequivalence of two formulations of Valsartan/Amlodipine Tablet(I) in healthy Chinese volunteers: A randomized, three-period, partially replicated crossover study.</ArticleTitle><Pagination><StartPage>2664</StartPage><MedlinePgn>2664</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2664</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-32576-9</ELocationID><Abstract><AbstractText>Valsartan/amlodipine combination tablets can exert synergistic antihypertensive effects through different mechanisms, significantly lowering blood pressure while also addressing multiple risk factors and comorbidities in patients. This study designed a single-center, randomized, open-label, two-formulations, single-dose, three-cycle, three-sequence, partially repeated crossover controlled trial design. A total of 72 healthy Chinese volunteers participated in the fasting and fed trials, of whom 69 completed the trial process. This study employed a methodologically validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine the concentrations of valsartan and amlodipine in plasma. Phoenix WinNonlin software (version 7.0) was used to calculate pharmacokinetic parameters using a non-compartmental model. Equivalence analysis was performed using the average bioequivalence (ABE) method and the reference-scaled average bioequivalence (RSABE) method. The trial results showed that the test drug was bioequivalent to the reference drug, and no suspected serious adverse reactions or serious adverse events occurred throughout the trial. The results of this study support the launch of the new generic Valsartan/Amlodipine Tablet(I) in China. As a representative antihypertensive fixed-dose combination (FDC), these methodological insights can be directly applied to clinical trials of similar drug products, thereby enhancing success rates while mitigating development risks.Clinical trial registration: CTR20221889, ( http://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml.28/07/2022 ).</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Research Laboratory, Xinxiang Central Hospital, No. 56 of Jinsui Street, Weibin District, Xinxiang, 453000, Henan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Clinical College of Henan Medical University, Xinxiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Research Laboratory, Xinxiang Central Hospital, No. 56 of Jinsui Street, Weibin District, Xinxiang, 453000, Henan Province, China. Zuoxu19850801@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Clinical College of Henan Medical University, Xinxiang, China. Zuoxu19850801@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tiandong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Research Laboratory, Xinxiang Central Hospital, No. 56 of Jinsui Street, Weibin District, Xinxiang, 453000, Henan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Clinical College of Henan Medical University, Xinxiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Ziyun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Research Laboratory, Xinxiang Central Hospital, No. 56 of Jinsui Street, Weibin District, Xinxiang, 453000, Henan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Clinical College of Henan Medical University, Xinxiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhendan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trial Research Laboratory, Xinxiang Central Hospital, No. 56 of Jinsui Street, Weibin District, Xinxiang, 453000, Henan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Clinical College of Henan Medical University, Xinxiang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No. LHGJ20221004</GrantID><Agency>Henan Province Medical Science and Technology Tackling Program Joint Co-Construction Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1J444QC288</RegistryNumber><NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000068838">Amlodipine, Valsartan Drug Combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical><Chemical><RegistryNumber>80M03YXJ7I</RegistryNumber><NameOfSubstance UI="D000068756">Valsartan</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Population" UI="C000724312">Chinese people</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017311" MajorTopicYN="Y">Amlodipine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068838" MajorTopicYN="Y">Amlodipine, Valsartan Drug Combination</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068756" MajorTopicYN="Y">Valsartan</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N" AutoHM="Y">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioequivalence</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Valsartan/Amlodipine Tablet(I)</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests. Ethics: The study protocol and informed consent documents were approved by the Ethics Committee of Xinxiang Central Hospital (Approval Nos. 2021-039, 2022&#x2009;&#x2212;&#x2009;249, and 2022&#x2009;&#x2212;&#x2009;537). Written informed consent was obtained from all participates. The trial was conducted following the Declaration of Helsinki, Good clinical practice (GCP) and the guidelines of China National Medical Products Administration (NMPA).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>22</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>0</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41390557</ArticleId><ArticleId IdType="pmc">PMC12824408</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-32576-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-32576-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ma, L. Y., Wang, Z. W., Fan, J. &amp; Hu, S. S. Epidemiology and management of hypertension in China: an analysis using data from the <i>Annual Report on Cardiovascular Health and Diseases in China Chinese General Practice.</i> 25,3715&#x2013;3720(2022). (2021).</Citation></Reference><Reference><Citation>Yu, Y. &amp; Pan, J. J. Research progress on the pathogenesis of central sympathetic nervous system in essential hypertension. <i>Chin. J. Cardiovasc. Med.</i><b>27</b>, 503&#x2013;506 (2022).</Citation></Reference><Reference><Citation>Ma, J. &amp; Chen, X. Advances in pathogenesis and treatment of essential hypertension. <i>Frontiers in cardiovascular medicine</i>. <b>14</b>(9), 1003852. 10.3389/fcvm.2022.1003852. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9616110</ArticleId><ArticleId IdType="pubmed">36312252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension Alliance (China) et al. 2024 Chinese guidelines for the management of hypertension (Revised Edition). <i>Chin. J. Hypertens.</i><b>32</b>, 603&#x2013;700 (2024).</Citation></Reference><Reference><Citation>Bo, Q. et al. Pharmacokinetics and safety of highly variable Valsartan in single-pill combination with amlodipine versus its generic formulation: a randomized,three-cycle, three-sequence, partially replicated crossover phase I bioequivalence clinical trial. <i>Front. Pharmacol.</i><b>14</b>, 1264321 10.3389/fphar.2023.1264321. (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10512707</ArticleId><ArticleId IdType="pubmed">37745062</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima, A. et al. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. <i>Xenobiotica</i><b>35</b>, 589&#x2013;602 (2005).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00498250500158175</ArticleId><ArticleId IdType="pubmed">16192110</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Q. et al. Pharmacokinetics and bioequivalence of two formulations of Valsartan 80&#xa0;mg capsules: A randomized, single dose, 4-period crossover study in healthy Chinese volunteers under fasting and fed conditions. <i>DDDT</i><b>14</b>, 4221&#x2013;4230 (2020).
</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S253078</ArticleId><ArticleId IdType="pmc">PMC7567554</ArticleId><ArticleId IdType="pubmed">33116410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, X. H. et al. Bioequivalence study of Valsartan/Amlodipine combination tablets in healthy Chinese volunteers. <i>Chin. J. Mod. Appl. Pharm.</i><b>37</b>, 1483&#x2013;1488 (2020).</Citation></Reference><Reference><Citation>Muzaffar Iqbal. Pharmacokinetics and bioequivalence study of three oral formulations of Valsartan 160&#xa0;mg: A Single-Dose, Randomized, Open-Label, three-Period crossover comparison in healthy Indian male volunteers. <i>Clin. Ther.</i><b>32</b>, 588&#x2013;596 (2010).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2010.03.004</ArticleId><ArticleId IdType="pubmed">20399995</ArticleId></ArticleIdList></Reference><Reference><Citation>Endrenyi, L. et al. Sample sizes for designing bioequivalence studies for highly variable drugs. <i>J. Pharm. Pharm. Sci.</i><b>15</b>, 73 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.18433/J3Z88F</ArticleId><ArticleId IdType="pubmed">22365089</ArticleId></ArticleIdList></Reference><Reference><Citation>Tothfalusi, L. et al. Algorithms for evaluating reference scaled average bioequivalence: Power, bias, and consumer risk. <i>Stat. Med.</i><b>36</b>, 4378&#x2013;4390 (2017).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7440</ArticleId><ArticleId IdType="pubmed">28850696</ArticleId></ArticleIdList></Reference><Reference><Citation>NMPA. Guidelines for selection and determination of reference preparations for common oral solid preparations. Mar (2016). https://www.nmpa.gov.cn/directory/web/nmpa/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html. Last access data 30 Jul, 2025.</Citation></Reference><Reference><Citation>NMPA. Guidelines for the Management of Drug Phase I Clinical Trials (Draft). Dec (2011). https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20111202113101617.html. Last access data 30 Jul, 2025.</Citation></Reference><Reference><Citation>NMPA. Technical Guidelines for Human Bioequivalence Studies of Generic Chemical Drugs Using Pharmacokinetic Parameters as Endpoint Indicators. Mar (2016). https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20160318210001725.html. Last access data 30 Jul, 2025.</Citation></Reference><Reference><Citation>NMPA. Technical Guidelines for Human Bioavailability and Bioequivalence Studies of Innovative Drugs. https://www.cde.org.cn/main/news/viewInfoCommon/34d91794def0eed2bb15c48ac496c76a. (2025). Last access data 30 Jul.</Citation></Reference><Reference><Citation>Ju-Hyun, N. et al. Pharmacokinetic comparison of amlodipineadipate/valsartan and amlodipine besylate/valsartan as fixed-dose combinations in healthy volunteers. <i>Int. J. Clin. Pharmacol. Ther.</i><b>53</b>, 66&#x2013;74 (2015).
</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CP202045</ArticleId><ArticleId IdType="pubmed">25034618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hee Youn Choi. Pharmacokinetics, Tolerability, and safety of the single oral administration of AGSAV301 vs exforge: A randomized crossover study of healthy male volunteers. <i>Am. J. Cardiovasc. Drugs</i>. <b>14</b>, 63&#x2013;72 (2014).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40256-013-0051-2</ArticleId><ArticleId IdType="pubmed">24174172</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, R. J., Xue, M., Gao, L. Y. &amp; Li, R. Y. Study on the relative bioavailability and bioequivalence of different amlodipine besylate tablets in humans. <i>Chin. J. Integr. Med. cardio-cerebrovascular Disease</i>. <b>17</b>, 2148&#x2013;2151 (2019).</Citation></Reference><Reference><Citation>Guidelines for the Validation of Quantitative Analytical Methods for Biological Samples. Edition of the Pharmacopoeia of the People&#x2019;s Republic of China (Part IV). (2020). https://ydz.chp.org.cn/#/item?bookId=4&amp;entryId=6075. Last access data 30 Jul, 2025.</Citation></Reference><Reference><Citation>NMPA. Technical Guidelines for Bioequivalence Studies of Highly Variable Drugs. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20181029173101911.html. (2025). Last access data 30 Jul.</Citation></Reference><Reference><Citation>Abuhelwa, A. Y., Williams, D. B., Upton, R. N. &amp; Foster, D. J. R. Food, Gastrointestinal pH, and models of oral drug absorption. <i>Eur. J. Pharm. Biopharm.</i><b>112</b>, 234&#x2013;248 (2017).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2016.11.034</ArticleId><ArticleId IdType="pubmed">27914234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y., Ingelman-Sundberg, M. &amp; Lauschke, V. Worldwide distribution of cytochrome P450 alleles: A meta-analysis of population-scale sequencing projects. <i>Clin. Pharmacol. Ther.</i><b>102</b>, 688&#x2013;700 (2017).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.690</ArticleId><ArticleId IdType="pmc">PMC5600063</ArticleId><ArticleId IdType="pubmed">28378927</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangadhar Sunkara. et al. Effect of food on the oral bioavailability of Amlodipine/Valsartan and Amlodipine/Valsartan/Hydrochlorothiazide fixed dose combination tablets in healthy subjects. <i>Clinical Pharmacol. Drug Development</i>. <b>3</b>, 487&#x2013;492 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">27129123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yukyung Kim. Pharmacokinetic comparison of 2 Fixed-Dose combination tablets of amlodipine and Valsartan in healthy male Korean volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, crossover study. <i>Clin. Ther.</i><b>35</b>, 934&#x2013;940 (2013).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2013.05.021</ArticleId><ArticleId IdType="pubmed">23870605</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41355387</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-6543</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>2</Issue><PubDate><Year>2026</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Current opinion in nephrology and hypertension</Title><ISOAbbreviation>Curr Opin Nephrol Hypertens</ISOAbbreviation></Journal><ArticleTitle>Methotrexate nephrotoxicity: a pragmatic approach.</ArticleTitle><Pagination><StartPage>212</StartPage><EndPage>217</EndPage><MedlinePgn>212-217</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MNH.0000000000001144</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">High-dose methotrexate (HDMTX) is an integral component of treatment for multiple malignancies. However, preventive strategies often fail, resulting in renal impairment and delayed methotrexate elimination (DME), which increases the risk of systemic toxicity. This review aims to summarize past, current, and emerging strategies for the management of HDMTX-related toxicity.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Recent research has identified host genetic factors, hypoalbuminemia, and larger body surface area as contributors to DME. Animal studies have explored potential nephroprotective agents, including synthetic 1,3,4-oxadiazole (5b) and repurposed drugs such as empagliflozin and amlodipine. The preferred mitigation agent, glucarpidase, continues to demonstrate improved clinical and financial outcomes, with higher odds of renal recovery even at lower doses. Early therapeutic drug monitoring has shown promise as a biomarker for predicting acute kidney injury. In addition, the web-based clinical tool MTXPK.org now integrates population pharmacokinetic models with patient-specific data to guide interpretation and management of DME.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Identification of emerging risk factors, advances in pharmacogenomics, and timely methotrexate monitoring, combined with patient-specific pharmacokinetic modeling, underscore the importance of personalized therapeutic strategies to reduce renal toxicity and DME.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mouawad</LastName><ForeName>Yara</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Renal Diseases and Hypertension, Department of Internal Medicine, University of Texas Health Science Center-McGovern Medical School, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kala</LastName><ForeName>Jaya</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Nephrol Hypertens</MedlineTA><NlmUniqueID>9303753</NlmUniqueID><ISSNLinking>1062-4821</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="Y">Methotrexate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="Y">Kidney Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="Y">Kidney</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000964" MajorTopicYN="Y">Antimetabolites, Antineoplastic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute kidney injury</Keyword><Keyword MajorTopicYN="N">delayed methotrexate elimination</Keyword><Keyword MajorTopicYN="N">glucarpidase</Keyword><Keyword MajorTopicYN="N">high-dose methotrexate</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>29</Day><Hour>7</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>2</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41355387</ArticleId><ArticleId IdType="doi">10.1097/MNH.0000000000001144</ArticleId><ArticleId IdType="pii">00041552-202603000-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Widemann BC, Schwartz S, Jayaprakash N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy 2014; 34:427&#x2013;439.</Citation></Reference><Reference><Citation>Latcha S, Gupta M, Lin IH, Jaimes EA. High dose methotrexate-induced acute kidney injury: incidence, risk factors, and recovery. Kidney Int Rep 2023; 8:360&#x2013;364.</Citation></Reference><Reference><Citation>Tentoni N, Hwang M, Villanueva G, et al. Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: a retrospective cohort study. Cancer Med 2024; 13:e70176.</Citation></Reference><Reference><Citation>Suthandiram S, Gan GG, Zain SM, et al. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics 2014; 15:1479&#x2013;1494.</Citation></Reference><Reference><Citation>Pitakkitnukun P, Pongpitakmetha T, Suttichet TB, et al. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate. Sci Rep 2024; 14:9695.</Citation></Reference><Reference><Citation>Choi JY, Kwon H, Kim H, et al. Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia. Front Pharmacol 2024; 15:1480657.</Citation></Reference><Reference><Citation>Wiczer T, Dotson E, Tuten A, et al. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract 2016; 22:430&#x2013;436.</Citation></Reference><Reference><Citation>Reiss SN, Buie LW, Adel N, et al. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol 2016; 95:2009&#x2013;2015.</Citation></Reference><Reference><Citation>Christensen SR, Jensen CF, Heldrup J, et al. Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to asparaginase therapy and impact on high dose methotrexate elimination. Cancer Chemother Pharmacol 2024; 94:775&#x2013;785.</Citation></Reference><Reference><Citation>O&#x2019;Donoghue DF, Truong HL, Finnes HD, et al. High-dose methotrexate in patients with lymphoma: predictors of a complicated course. JCO Oncol Pract 2022; 18:e1908&#x2013;e1917.</Citation></Reference><Reference><Citation>Buddington RK, Wong T, Buddington KK, et al. Early clinical indicators of acute kidney injury caused by administering high-dose methotrexate therapy to juvenile pigs. Front Nephrol 2023; 3:1193494.</Citation></Reference><Reference><Citation>Lin WY, Tsai CK, Yeh CM, Liu CJ. Identifying risk factors for methotrexate-induced acute kidney injury despite full prevention in patients with primary central nervous system lymphoma. Toxicol Appl Pharmacol 2025; 502:117436.</Citation></Reference><Reference><Citation>Rafique Z, Aabid M, Nadeem H, et al. Nephroprotective potential of 1,3,4-oxadiazole derivative against methotrexate-induced nephrotoxicity in rats by upregulating Nrf2 and downregulating NF-kappaB and TNF-alpha signaling pathways. J Biochem Mol Toxicol 2024; 38:e70084.</Citation></Reference><Reference><Citation>Mishriki AA, Khalifa AK, Ibrahim DA, et al. Empagliflozin mitigates methotrexate-induced nephrotoxicity in male albino rats: insights on the crosstalk of AMPK/Nrf2 signaling pathway. Future J Pharm Sci 2024; 10:95.</Citation></Reference><Reference><Citation>Karim S, Kutbi D, Alkreathy H, et al. Amlodipine protects against methotrexate nephrotoxicity by modulating inflammation, oxidative stress, and apoptosis through NF-(B/PPAR-(/caspase 3 pathways. J Adv Pharm Educ Res 2024; 14:7&#x2013;17.</Citation></Reference><Reference><Citation>Gupta S, Kaunfer SA, Chen KL, et al. Glucarpidase for treatment of high-dose methotrexate toxicity. Blood 2025; 145:1858&#x2013;1869.</Citation></Reference><Reference><Citation>Demiralp B, Koenig L, Kala J, et al. Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study. Clinicoecon Outcomes Res 2019; 11:129&#x2013;144.</Citation></Reference><Reference><Citation>Schaff LR, Lobbous M, Carlow D, et al. Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multicenter phase I study. BMC Cancer 2022; 22:60.</Citation></Reference><Reference><Citation>Kala J, Nelson R, Drudge C, et al. Glucarpidase for treating adults with delayed methotrexate elimination due to impaired renal function: an economic simulation analysis. Clinicoecon Outcomes Res 2023; 15:165&#x2013;179.</Citation></Reference><Reference><Citation>Tome ACN, Santos KF, Lima EQ, Ramalho RJ. High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights. Front Med (Lausanne) 2025; 12:1495705.</Citation></Reference><Reference><Citation>Ghannoum M, Roberts DM, Goldfarb DS, et al. Extracorporeal treatment for methotrexate poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol 2022; 17:602&#x2013;622.</Citation></Reference><Reference><Citation>Ramsey LB, Balis FM, O&#x2019;Brien MM, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 2018; 23:52&#x2013;61.</Citation></Reference><Reference><Citation>Bielack SS, Soussain C, Fox CP, et al. A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. J Cancer Res Clin Oncol 2024; 150:441.</Citation></Reference><Reference><Citation>Taylor ZL, Mizuno T, Punt NC, et al. MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase. Clin Pharmacol Ther 2020; 108:635&#x2013;643.</Citation></Reference><Reference><Citation>Taylor ZL, Miller TP, Poweleit EA, et al. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Clin Transl Sci 2023; 16:2130&#x2013;2143.</Citation></Reference><Reference><Citation>Garre ML, Relling MV, Kalwinsky D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 1987; 111:606&#x2013;612.</Citation></Reference><Reference><Citation>Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978; 23:68&#x2013;72.</Citation></Reference><Reference><Citation>Taylor ZL, Miller TP, Board SG, et al. What is the expected clearance of methotrexate? A therapeutic drug monitoring reference guide for high-dose methotrexate use in pediatric malignancies. Pediatr Blood Cancer 2025; 72:e31744.</Citation></Reference><Reference><Citation>Yang L, Yang S, Zhang T, et al. Point-of-care testing of methotrexate using a controlled release sensor based on a personal glucose meter. Anal Methods 2025; 17:1345&#x2013;1353.</Citation></Reference><Reference><Citation>Liu H, Liu YW, Yang RY, et al. Therapeutic drug monitoring of methotrexate by disposable SPCE biosensor for personalized medicine. Anal Chim Acta 2025; 1335:343473.</Citation></Reference><Reference><Citation>Shao W, Liu X, Zhou Y. Magnetic separation-assisted DNAzyme walker-based nanosensor for point-of-care therapeutic drug monitoring of methotrexate. Talanta 2025; 285:127387.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41334613</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4286</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Current pharmaceutical design</Title><ISOAbbreviation>Curr Pharm Des</ISOAbbreviation></Journal><ArticleTitle>Multi-Segmental Evaluation of Intestinal Permeability of Amlodipine at Two Dose Levels.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/0113816128381339250422080602</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Intestinal permeability plays a crucial role in drug absorption, as it varies across different gastrointestinal regions, affecting the bioavailability of orally administered drugs. This variability, combined with dose-dependent absorption, influences the overall efficacy and pharmacokinetics of the drug.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to investigate the impact of three intestinal regions (jejunum, ileum, and colon) along with two different doses of amlodipine (AML) (5 mg and 10 mg) on its permeability.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">An optimized HPLC method was developed and validated for the simultaneous quantification of AML, metoprolol (MTP), and phenol red (PR), while a modified single-pass intestinal perfusion (SPIP) was used to assess AML permeability across different intestinal segments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Net Water Flux (NWF) showed significant fluctuations, with high positive values in the colon, indicating distinct physiological responses in this region. The effective permeability (Peff) of AML varied across different intestinal segments and doses. In the jejunum and ileum, the Peff of AML decreased with increasing doses from 5 mg to 10 mg, while in the colon, Peff remained relatively stable. Peff values ranged from 3.50 &#xd7; 10-4 cm/s for the 5 mg dose to 1.80 &#xd7; 10-4 cm/s for the 10 mg dose in the jejunum, from 3.30 &#xd7; 10-4 cm/s (5 mg) to 2.41 &#xd7; 10-4 cm/s (10 mg) in the ileum, and from 6.65 &#xd7; 10-4 cm/s (5 mg) to 6.79 &#xd7; 10-4 cm/s (10 mg) in the colon.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrated significant segmental and dose-dependent variations in the intestinal permeability of AML using the SPIP model in rats.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ate&#x15f;</LastName><ForeName>M&#xfc;ge</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0007-0235-6982</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, &#x130;n&#xf6;n&#xfc; University, Malatya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stelmasi&#x144;ska</LastName><ForeName>Agata Bogacz</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, &#x130;n&#xf6;n&#xfc; University, Malatya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stelmasi&#x144;ska</LastName><ForeName>Micha&#x142;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, &#x130;n&#xf6;n&#xfc; University, Malatya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barre</LastName><ForeName>Liban</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8075-6622</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskisehir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;y&#xfc;ktuncel</LastName><ForeName>Ebru</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3601-3316</Identifier><AffiliationInfo><Affiliation>Department of Analytical Chemistry, Faculty of Pharmacy, &#x130;n&#xf6;n&#xfc; University, Malatya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaynak</LastName><ForeName>Mustafa Sinan</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskisehir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x15e;ahin</LastName><ForeName>Selma</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5736-5906</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Pharm Des</MedlineTA><NlmUniqueID>9602487</NlmUniqueID><ISSNLinking>1381-6128</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amlodipine</Keyword><Keyword MajorTopicYN="N">Perfusion coefficient</Keyword><Keyword MajorTopicYN="N">SPIP.</Keyword><Keyword MajorTopicYN="N">drug absorption</Keyword><Keyword MajorTopicYN="N">ileum</Keyword><Keyword MajorTopicYN="N">intestinal permeability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>7</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>7</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>5</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41334613</ArticleId><ArticleId IdType="doi">10.2174/0113816128381339250422080602</ArticleId><ArticleId IdType="pii">CPD-EPUB-151966</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41308787</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6017</ISSN><JournalIssue CitedMedium="Internet"><Volume>115</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of pharmaceutical sciences</Title><ISOAbbreviation>J Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>Biowaiver monograph for immediate-release solid oral dosage forms: Amlodipine besylate.</ArticleTitle><Pagination><StartPage>104108</StartPage><MedlinePgn>104108</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xphs.2025.104108</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3549(25)00562-3</ELocationID><Abstract><AbstractText>Amlodipine besylate is a calcium channel blocker widely used for treating hypertension and coronary artery disease. This biowaiver monograph evaluates the suitability of BCS-based biowaivers for immediate-release (IR) oral dosage forms containing amlodipine besylate. A comprehensive review of available data was conducted to assess solubility, permeability, bioavailability, dissolution, pharmacokinetics, safety, and excipient interactions. Amlodipine besylate is a highly soluble base across the pH range 1.2-6.8. Although mass balance in humans showed a fraction absorbed of &#x2265;96%, inconclusive in vitro permeability data revealed a risk associated with a BCS class I classification. Nonetheless, several IR formulations, including fixed-dose combinations (FDC), have demonstrated bioequivalence (BE). This has been related to very rapid in vitro dissolution profiles at 75 rpm for the reference product, as recommended by guidelines. Taken together, the risk of BE failure due to formulation or manufacturing differences is low, provided a very rapid dissolution and the use of standard excipients. With a favorable safety profile and a wide therapeutic index, the overall evidence leads to a conservative classification of amlodipine besylate to BCS III. Thus, IR products containing this drug can be candidates for the BCS-based biowaiver, thereby enabling substitution of surrogate in vitro methods for in vivo BE approval of multisource products.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de la Cruz-Cruz</LastName><ForeName>Porfirio</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Doctorado Institucional en Ingenier&#xed;a y Ciencia de Materiales (DICIM), Universidad Aut&#xf3;noma de San Luis Potos&#xed;, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Mauricio A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Departamento de Farmacia, Escuela de Qu&#xed;mica y Farmacia, Facultad de Qu&#xed;mica y de Farmacia, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, 7820436, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Urizar</LastName><ForeName>Jos&#xe9; Trinidad</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Facultad de Ciencias Qu&#xed;micas, Universidad Aut&#xf3;noma de San Luis Potos&#xed;, Mexico; FS SCIENTIA PHARMA S.A. de C.V (Authorized Third Party), San Luis Potos&#xed;, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahamsson</LastName><ForeName>Bertil</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Oral Product Development, Pharmaceutical Technology &amp; Development, Operations, AstraZeneca Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristofoletti</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kambayashi</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Mehul</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>United States Food and Drug Administration, Centre for Drug Evaluation and Research, Silver Spring, MD 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parr</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>BioCeutics LLC, Cary, NC 27511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polli</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 20742, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Vinod P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Pharmaceutical Consultant, Richmond, VA 23233, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charoo</LastName><ForeName>Naseem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Wissen Healthcare LLC, Al Barsha, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talath</LastName><ForeName>Sirajunisa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, RAK College of Pharmacy, RAK Medical &amp; Health Sciences University, P.O. Box 11172, Ras Al Khaimah, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dressman</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Heraclitus Advisors Pty. Ltd., Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langguth</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany. Electronic address: langguth@uni-mainz.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharm Sci</MedlineTA><NlmUniqueID>2985195R</NlmUniqueID><ISSNLinking>0022-3549</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amlodipine besylate</Keyword><Keyword MajorTopicYN="N">Bioequivalence (BE)</Keyword><Keyword MajorTopicYN="N">Biopharmaceutics classification system (BCS)</Keyword><Keyword MajorTopicYN="N">Biowaiver</Keyword><Keyword MajorTopicYN="N">Dissolution</Keyword><Keyword MajorTopicYN="N">Permeability</Keyword><Keyword MajorTopicYN="N">Physiologically based biopharmaceutics models (PBBM)</Keyword><Keyword MajorTopicYN="N">Solubility</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>27</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41308787</ArticleId><ArticleId IdType="doi">10.1016/j.xphs.2025.104108</ArticleId><ArticleId IdType="pii">S0022-3549(25)00562-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>